332 related articles for article (PubMed ID: 1803343)
1. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms.
Nau H; Hauck RS; Ehlers K
Pharmacol Toxicol; 1991 Nov; 69(5):310-21. PubMed ID: 1803343
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid-induced neural tube defects.
Nau H
Ciba Found Symp; 1994; 181():144-52; discussion 152-60. PubMed ID: 8005022
[TBL] [Abstract][Full Text] [Related]
3. Asymmetric synthesis and enantioselective teratogenicity of 2-n-propyl-4-pentenoic acid (4-en-VPA), an active metabolite of the anticonvulsant drug, valproic acid.
Hauck RS; Nau H
Toxicol Lett; 1989 Oct; 49(1):41-8. PubMed ID: 2510370
[TBL] [Abstract][Full Text] [Related]
4. The valproic acid metabolite E-2-n-propyl-2-pentenoic acid does not induce spina bifida in the mouse.
Ehlers K; Stürje H; Merker HJ; Nau H
Dev Pharmacol Ther; 1992; 19(4):196-204. PubMed ID: 1343622
[TBL] [Abstract][Full Text] [Related]
5. Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics.
Ehlers K; Elmazar MM; Nau H
J Nutr; 1996 Jan; 126(1):67-75. PubMed ID: 8558327
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid-induced spina bifida: a mouse model.
Ehlers K; Stürje H; Merker HJ; Nau H
Teratology; 1992 Feb; 45(2):145-54. PubMed ID: 1377411
[TBL] [Abstract][Full Text] [Related]
7. Prediction of embryotoxic effects of valproic acid-derivatives with molecular in vitro methods.
Lampen A; Göttlicher M; Nau H
ALTEX; 2001; 18(2):123-6. PubMed ID: 11378687
[TBL] [Abstract][Full Text] [Related]
8. The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity in mice.
Hauck RS; Nau H
Pharm Res; 1992 Jul; 9(7):850-5. PubMed ID: 1437995
[TBL] [Abstract][Full Text] [Related]
9. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
Nau H
Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic evaluation of various metabolites and analogs of valproic acid: teratogenic potencies in mice.
Nau H; Löscher W
Fundam Appl Toxicol; 1986 May; 6(4):669-76. PubMed ID: 3086174
[TBL] [Abstract][Full Text] [Related]
11. Amelioration of sodium valproate-induced neural tube defects in mouse fetuses by maternal folic acid supplementation during gestation.
Padmanabhan R; Shafiullah MM
Congenit Anom (Kyoto); 2003 Mar; 43(1):29-40. PubMed ID: 12692401
[TBL] [Abstract][Full Text] [Related]
12. Hydroxamic acid and fluorinated derivatives of valproic acid: anticonvulsant activity, neurotoxicity and teratogenicity.
Gravemann U; Volland J; Nau H
Neurotoxicol Teratol; 2008; 30(5):390-4. PubMed ID: 18455366
[TBL] [Abstract][Full Text] [Related]
13. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis.
Wegner C; Nau H
Neurology; 1992 Apr; 42(4 Suppl 5):17-24. PubMed ID: 1574172
[TBL] [Abstract][Full Text] [Related]
14. S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
Eikel D; Hoffmann K; Zoll K; Lampen A; Nau H
Drug Metab Dispos; 2006 Apr; 34(4):612-20. PubMed ID: 16415118
[TBL] [Abstract][Full Text] [Related]
15. Validation of an in vitro teratology system using chiral substances: stereoselective teratogenicity of 4-yn-valproic acid in cultured mouse embryos.
Andrews JE; Ebron-McCoy M; Bojic U; Nau H; Kavlock RJ
Toxicol Appl Pharmacol; 1995 Jun; 132(2):310-6. PubMed ID: 7785058
[TBL] [Abstract][Full Text] [Related]
16. Trimethoprim potentiates valproic acid-induced neural tube defects (NTDs) in mice.
Elmazar MM; Nau H
Reprod Toxicol; 1993; 7(3):249-54. PubMed ID: 8318756
[TBL] [Abstract][Full Text] [Related]
17. The enantioselective teratogenicity of 2-n-propyl-4-pentynoic acid (4-yn-VPA) is due to stereoselective intrinsic activity and not differences in pharmacokinetics.
Hauck RS; Elmazar MM; Plum C; Nau H
Toxicol Lett; 1992 Apr; 60(2):145-53. PubMed ID: 1570629
[TBL] [Abstract][Full Text] [Related]
18. Spina bifida aperta induced by valproic acid and by all-trans-retinoic acid in the mouse: distinct differences in morphology and periods of sensitivity.
Ehlers K; Stürje H; Merker HJ; Nau H
Teratology; 1992 Aug; 46(2):117-30. PubMed ID: 1440416
[TBL] [Abstract][Full Text] [Related]
19. Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect.
Bojic U; Elmazar MM; Hauck RS; Nau H
Chem Res Toxicol; 1996; 9(5):866-70. PubMed ID: 8828922
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): cross-species evaluation in whole embryo culture.
Andrews JE; Ebron-McCoy MT; Bojic U; Nau H; Kavlock RJ
Teratology; 1997 May; 55(5):314-8. PubMed ID: 9261925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
